In the era of 100-year life spans, will esaxerenone be positioned as a second-line treatment for any age group?

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research Pub Date : 2025-03-28 DOI:10.1038/s41440-025-02133-y

Tetsuro Yoshida

引用次数: 0

Abstract Image

查看原文本刊更多论文

在人均寿命达到 100 岁的时代，艾塞瑞酮是否会被定位为任何年龄段人群的二线治疗药物？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hypertension Research 医学-外周血管病

CiteScore

7.40

自引率

16.70%

发文量

249

审稿时长

3-8 weeks

期刊介绍： Hypertension Research is the official publication of the Japanese Society of Hypertension. The journal publishes papers reporting original clinical and experimental research that contribute to the advancement of knowledge in the field of hypertension and related cardiovascular diseases. The journal publishes Review Articles, Articles, Correspondence and Comments.